Alumis Inc. ALMS
Alumis Inc. (Nasdaq: ALMS) is an immunology/inflammation drug developer. Its lead program, envudeucitinib (envu, formerly ESK-001), is in Phase 3 for moderate-to-severe plaque psoriasis. Its next catalyst on record is A-005: Initiate Phase 2 biomarker trial in Parkinson's disease (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: A-005 — Initiate Phase 2 biomarker trial in Parkinson's disease (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| envudeucitinib (envu) | plaque psoriasis (pivotal Phase 3 ONWARD1/ONWARD2 complete; ONWARD3 LTE ongoing) | small molecule | Phase 3 |
| envudeucitinib (envu) | systemic lupus erythematosus | small molecule | Phase 2 |
| A-005 | CNS / neuroinflammatory disease (Parkinson's disease biomarker trial planned) | small molecule | Phase 1 |
| lonigutamab | thyroid eye disease | antibody | Phase 1 |
Recent results and decisions
- Sep 1, 2026missed Phase 2b LUMUS did not meet its primary (BICLA Week 48) or secondary endpoints in the overall population (n=408); responses seen in prespecified IFNGS-high subgroup.
LUMUS trial did not meet its primary and secondary endpoints in the overall trial population
Filing - Aug 10, 2026positive ONWARD3 long-term extension: after up to 48 weeks of continuous treatment 75% reached PASI 90 and 54% PASI 100 (n=773), with no new safety signals.
75% and 54% of patients achieved PASI 90 and PASI 100, respectively
Filing - May 14, 2026n/a Alumis completed its strategic review of lonigutamab and decided to explore strategic alternatives for the asset.
Alumis has completed its strategic review of the lonigutamab program and decided to explore strategic alternatives for this asset.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.